» Articles » PMID: 6188871

Biological Response Modifiers

Overview
Specialty Oncology
Date 1983 May 1
PMID 6188871
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

It is clear that the rate of change in biology is rapidly accelerating. This is most apparent in the BRM area with respect to the development of new cancer therapies. New surgical approaches are being developed, and new forms of delivery for therapeutic radiation are now available. Radiosensitizers are now also being tested. Similarly, new chemotherapeutic agents and new methods of utilizing existing drugs are being developed. However, the use of BRM either alone or in combination with these other modalities is the area of greatest change and can be expected to be a major factor in achieving a greater understanding of cancer biology and a greater therapeutic specificity in the treatment of cancer patients in this decade (2, 65). Given the new technology of the 1980's, this is an exciting time. It is hoped that sufficient resources will be available to support continuing efforts to develop biologicals into effective anticancer agents. The rapidly advancing technologies of computers, cell fusion, and genetic engineering are all interrelated through the underpinnings of molecular biology to offer us unparalleled opportunities in biological research. These opportunities should translate into more effective treatments for cancer in this decade.

Citing Articles

Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis.

Wang H, Cai Y, Zheng Y, Bai Q, Xie D, Yu J Cancer Med. 2017; 6(10):2222-2233.

PMID: 28940986 PMC: 5633561. DOI: 10.1002/cam4.1156.


Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

Rusthoven J Int J Antimicrob Agents. 1994; 3(4):223-43.

PMID: 18611565 PMC: 7135342. DOI: 10.1016/0924-8579(94)90050-7.


Activation of protein kinase C by mycobacterial cord factor, trehalose 6-monomycolate, resulting in tumor necrosis factor-alpha release in mouse lung tissues.

Sueoka E, Nishiwaki S, Okabe S, Iida N, Suganuma M, Yano I Jpn J Cancer Res. 1995; 86(8):749-55.

PMID: 7559098 PMC: 5920914. DOI: 10.1111/j.1349-7006.1995.tb02464.x.


Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

Ozaki S, Okazaki T, Nakao K Cancer Immunol Immunother. 1995; 40(4):219-27.

PMID: 7538449 PMC: 11037815.


Granuloma formation and hemopoiesis induced by C36-48-mycolic acid-containing glycolipids from Nocardia rubra.

Kaneda K, Sumi Y, Kurano F, Kato Y, Yano I Infect Immun. 1986; 54(3):869-75.

PMID: 3781628 PMC: 260251. DOI: 10.1128/iai.54.3.869-875.1986.